OTCMKTS:ALPMY Astellas Pharma (ALPMY) Stock Price, News & Analysis $9.22 -0.12 (-1.28%) As of 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestBuy This Stock About Astellas Pharma Stock (OTCMKTS:ALPMY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Astellas Pharma alerts:Sign Up Key Stats Today's Range$9.22▼$9.3850-Day Range$9.15▼$10.0152-Week Range$9.05▼$13.14Volume173,075 shsAverage Volume187,289 shsMarket Capitalization$16.69 billionP/E RatioN/ADividend Yield3.58%Price TargetN/AConsensus RatingN/A Company OverviewAstellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.Read More… Remove Ads Receive ALPMY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Astellas Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address ALPMY Stock News HeadlinesSinglera Genomics Presented Non-Invasive Testicular Toxicity Detection with Astellas at 2025 SOT MeetingMarch 24, 2025 | globenewswire.comAstellas Pharma: Raising New, As Yet Unanswered Questions In Stomach Cancer And Moving Their Pipeline ForwardMarch 15, 2025 | seekingalpha.comYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. Now… as new tariffs take effect, gold is breaking records again. You've hopefully already seen this in action… but gold is surpassing $3,000 per ounce for the first time EVER.April 3, 2025 | Premier Gold Co (Ad)J.P. Morgan Remains a Hold on Astellas Pharma (ALPMF)March 8, 2025 | markets.businessinsider.comAstellas and Yaskawa form JV for cell therapy product manufactureMarch 7, 2025 | finance.yahoo.comAstellas and YASKAWA form JV focused on cell therapy manufacturingMarch 6, 2025 | msn.comAstellas and YASKAWA Agree to Establish a Joint Venture Focused on Cell Therapy ManufacturingMarch 6, 2025 | finance.yahoo.comAstellas and MBC BioLabs Announce the Sixth Annual Astellas Future Innovator PrizeFebruary 27, 2025 | prnewswire.comSee More Headlines ALPMY Stock Analysis - Frequently Asked Questions How have ALPMY shares performed this year? Astellas Pharma's stock was trading at $9.66 at the beginning of the year. Since then, ALPMY stock has decreased by 3.3% and is now trading at $9.34. View the best growth stocks for 2025 here. How were Astellas Pharma's earnings last quarter? Astellas Pharma Inc. (OTCMKTS:ALPMY) released its earnings results on Tuesday, February, 4th. The company reported $0.30 EPS for the quarter. Astellas Pharma had a positive trailing twelve-month return on equity of 13.69% and a negative net margin of 3.10%. When did Astellas Pharma's stock split? Astellas Pharma's stock split on Wednesday, April 2nd 2014. The 5-4 split was announced on Friday, March 14th 2014. The newly created shares were issued to shareholders after the market closes on Tuesday, April 1st 2014. An investor that had 100 shares of stock prior to the split would have 125 shares after the split. Does Astellas Pharma have any subsidiaries? Astellas Pharma subsidiaries include Iota Biosciences, Nanna Therapeutics, Xyphos, Audentes Therapeutics, Potenza Therapeutics, Quethera, Universal Cells Inc., and more. How do I buy shares of Astellas Pharma? Shares of ALPMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings2/04/2025Today4/03/2025Next Earnings (Estimated)4/24/2025Fiscal Year End3/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:ALPMY CIK1446390 Webwww.astellas.com Phone(133) 244-3000FaxN/AEmployees14,754Year Founded1923Profitability EPS (Most Recent Fiscal Year)($0.22) Trailing P/E RatioN/A Forward P/E Ratio21.95 P/E GrowthN/ANet Income$113 million Net Margins-3.10% Pretax MarginN/A Return on Equity13.69% Return on Assets6.06% Debt Debt-to-Equity Ratio0.39 Current Ratio1.04 Quick Ratio0.80 Sales & Book Value Annual Sales$11.11 billion Price / Sales1.50 Cash Flow$1.10 per share Price / Cash Flow8.42 Book Value$5.84 per share Price / Book1.58Miscellaneous Outstanding Shares1,809,663,000Free FloatN/AMarket Cap$16.69 billion OptionableNot Optionable Beta0.29 Social Links 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (OTCMKTS:ALPMY) was last updated on 4/3/2025 by MarketBeat.com Staff From Our Partners“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out firs...Paradigm Press | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredEU’s Action Takes Aim At US RetireesTrump's Return Sparks Massive Gold Rush—Is Your 401(k) Ready for the Fallout? With President Trump back and...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Astellas Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Astellas Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.